The impact of micronized progesterone on the endometrium: a systematic review

Climacteric

Volumn 19, Issue 4, 2016, Pages 316-328

  Stute, P ^a   Neulen, J ^b   Wildt, L ^c  

^a UNIVERSITY OF BERN   (Switzerland)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

combined estrogen progestogen therapy; endometrium; hormone therapy; menopause; Micronized progesterone

Indexed keywords

PROGESTERONE; GESTAGEN;

BIOSIS; CANCER INCIDENCE; COCHRANE LIBRARY; ENDOMETRIAL THICKNESS; ENDOMETRIUM; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; HISTOLOGY; HUMAN; MEDICAL SUBJECT HEADINGS; MEDLINE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TRANSVAGINAL ECHOGRAPHY; CUTANEOUS DRUG ADMINISTRATION; DRUG EFFECTS; ESTROGEN THERAPY; FEMALE; INTRAVAGINAL DRUG ADMINISTRATION; MENOPAUSE; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PROCEDURES; STANDARDS; UTERUS; VAGINA;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, ORAL; ENDOMETRIUM; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; PRACTICE GUIDELINES AS TOPIC; PROGESTERONE; PROGESTINS; UTERUS; VAGINA;

EID: 84977601728     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697137.2016.1187123     Document Type: Review

References (53)

1. A.I.Csapo, M.Pulkkinen Indispensability of the human corpus luteum in the maintenance of early pregnancy. Luteectomy evidence. Obstet Gynecol Surv 1978;33:69–81
2. T.J.de Villiers, A.Pines, N.Panay, et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013;16:316–37
3. X.Ruan, A.O.Mueck Systemic progesterone therapy – oral, vaginal, injections and even transdermal? Maturitas 2014;79:248–55
4. M.H.Birkhauser, N.Panay, D.F.Archer, et al. Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric 2008;11:108–23
5. C.Di Carlo, G.A.Tommaselli, V.Gargano, F.Savoia, G.Bifulco, C.Nappi Transdermal estradiol and oral or vaginal natural progesterone: bleeding patterns. Climacteric 2010;13:442–6
6. C.Di Carlo, A.Sammartino, A.Di Spiezio Sardo, et al. Bleeding patterns during continuous estradiol with different sequential progestogens therapy. Menopause 2005;12:520–5
7. N.E.Allen, K.K.Tsilidis, T.J.Key, et al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition. Am J Epidemiol 2010;172:1394–403
8. A.Fournier, L.Dossus, S.Mesrine, et al. Risks of endometrial cancer associated with different hormone replacement therapies in the E3N cohort, 1992–2008. Am J Epidemiol 2014;180:508–17
9. S.M.Harman, D.M.Black, F.Naftolin, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med 2014;161:249–60
10. I.I.Bolaji, G.Mortimer, H.Grimes, D.F.Tallon, E.O'Dwyer, P.F.Fottrell Clinical evaluation of near-continuous oral micronized progesterone therapy in estrogenized postmenopausal women. Gynecol Endocrinol 1996;10:41–7
11. I.I.Bolaji, G.Mortimer, H.Grimes, E.M.O'Dwyer Endometrial response in oestrogenised postmenopausal women after treatment with oral progesterone: results of a prospective analysis. J Obstet Gynaecol 1992;12:412–17
12. E.Darj, S.Nilsson, O.Axelsson, D.Hellberg Clinical and endometrial effects of oestradiol and progesterone in post-menopausal women. Maturitas 1991;13:109–15
13. A.Dupont, P.Dupont, L.Cusan, et al. Comparative endocrinological and clinical effects of percutaneous estradiol and oral conjugated estrogens as replacement therapy in menopausal women. Maturitas 1991;13:297–311
14. J.Y.Gillet, G.Andre, B.Faguer, et al. Induction of amenorrhea during hormone replacement therapy: optimal micronized progesterone dose. A multicenter study. Maturitas 1994;19:103–15
15. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996;275:370–5
16. J.T.Hargrove, W.S.Maxson, A.C.Wentz, L.S.Burnett Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstet Gynecol 1989;73:606–12
17. J.Holst, S.Cajander, B.von Schoultz Endometrial response in post-menopausal women during treatment with percutaneous 17 beta-oestradiol opposed by oral progesterone. Maturitas 1986;8:201–7
18. M.Jondet, M.Maroni, H.Yaneva, S.Brin, F.Peltier-Pujol, C.Pelissier Comparative endometrial histology in postmenopausal women with sequential hormone replacement therapy of estradiol and, either chlormadinone acetate or micronized progesterone. Maturitas 2002;41:115–21
19. G.Lane, N.C.Siddle, T.A.Ryder, J.Pryse-Davies, R.J.King, M.I.Whitehead Dose dependent effects of oral progesterone on the oestrogenised postmenopausal endometrium. Br Med J (Clin Res Ed) 1983;287:1241–5
20. D.L.Moyer, B.de Lignieres, P.Driguez, J.P.Pez Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes. Fertil Steril 1993;59:992–7
21. K.M.Prestwood, A.M.Kenny, A.Kleppinger, M.Kulldorff Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. JAMA 2003;290:1042–8
22. C.Pelissier, M.Maroni, H.Yaneva, S.Brin, F.Peltier-Pujol, M.Jondet Chlormadinone acetate versus micronized progesterone in the sequential combined hormone replacement therapy of the menopause. Maturitas 2001;40:85–94
23. E.Suvanto-Luukkonen, H.Sundstrom, J.Penttinen, A.Kauppila, E.M.Rutanen Insulin-like growth factor-binding protein-1: a biochemical marker of endometrial response to progestin during hormone replacement therapy. Maturitas 1995;22:255–62
24. D.L.Moyer, J.C.Felix, R.J.Kurman, C.A.Cuffie Micronized progesterone regulation of the endometrial glandular cycling pool. Int J Gynecol Pathol 2001;20:374–9
25. M.Marengo, V.Rodriguez Vidal, E.G.Deza Hormonal replacement therapy (HRT). Evaluation of a novel 25 days regimen with percutaneous estradiol (PE2) and micronized oral progesterone (MP). PAMI Institution: Sarmiento 373, Rosario, Argentina, 2000
26. J.M.Foidart, N.Dombrowicz, R.Greimers, M.Smet, B.de Lignieres Endometrial tolerance of long-term combined hormone replacement therapy: analysis of the cell cycle. In B.von Schoultz, C.Christiansen, eds. Hormone Replacement Therapy: standardized or Individually Adjusted Doses? Lancaster, UK: Parthenon Publishing, 1993:47–58
27. G.Antoniou, D.Kalogirou, P.Karakitsos, D.Antoniou, O.Kalogirou, L.Giannikos Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints versus estradiol-releasing vaginal ring with a vaginal progesterone suppository: clinical and endometrial responses. Maturitas 1997;26:103–11
28. A.Ben-Chetrit, D.Hochner-Celnikier, T.Lindenberg, et al. Vaginal ring delivering estradiol and progesterone: a possible alternative to relieve climacteric symptoms. Isr Med Assoc J 2005;7:302–6
29. D.de Ziegler, R.Ferriani, L.A.Moraes, C.Bulletti Vaginal progesterone in menopause: Crinone 4% in cyclical and constant combined regimens. Hum Reprod 2000;1(Suppl 1):149–58
30. L.Fernandez-Murga, C.Hermenegildo, J.J.Tarin, M.A.Garcia-Perez, A.Cano Endometrial response to concurrent treatment with vaginal progesterone and transdermal estradiol. Climacteric 2012;15:455–9
31. E.Cicinelli, D.de Ziegler, P.Galantino, et al. Twice-weekly transdermal estradiol and vaginal progesterone as continuous combined hormone replacement therapy in postmenopausal women: a 1-year prospective study. Am J Obstet Gynecol 2002;187:556–60
32. R.A.Miles, R.J.Paulson, R.A.Lobo, M.F.Press, L.Dahmoush, M.V.Sauer Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril 1994;62:485–90
33. E.Cicinelli, D.de Ziegler, R.Alfonso, R.Nicoletti, M.Bellavia, G.Colafiglio Endometrial effects, bleeding control, and compliance with a new postmenopausal hormone therapy regimen based on transdermal estradiol gel and every-other-day vaginal progesterone in capsules: a 3-year pilot study. Fertil Steril 2005;83:1859–63
34. G.Noe, R.Sitruk-Ware, F.Zegers-Hochschild, et al. Endometrial effect of progesterone delivered by vaginal rings in estrogen-treated postmenopausal women. Climacteric 2010;13:433–41
35. E.Suvanto-Luukkonen, H.Malinen, H.Sundstrom, J.Penttinen, A.Kauppila Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone. Acta Obstet Gynecol Scand 1998;77:758–63
36. L.C.Vilodre, M.C.Osorio Wender, J.A.Sisson de Castro, et al. Endometrial response to a cyclic regimen of percutaneous 17beta-estradiol and low-dose vaginal micronized progesterone in women with mild-to-moderate hypertension. Gynecol Endocrinol 2003;17:323–8
37. E.Cicinelli, V.Borraccino, D.Petruzzi, N.Mazzotta, M.L.Cerundolo, L.M.Schonauer Pharmacokinetics and endometrial effects of the vaginal administration of micronized progesterone in an oil-based solution to postmenopausal women. Fertil Steril 1996;65:860–2
38. S.Ferrero, D.Gerbaldo, E.Fulcheri, P.Cristoforoni Vaginal micronized progesterone in continuous hormone replacement therapy. A prospective randomized study. Minerva Ginecol 2002;54:519–30
39. D.Ross, A.J.Cooper, J.Pryse-Davies, C.Bergeron, W.P.Collins, M.I.Whitehead Randomized, double-blind, dose-ranging study of the endometrial effects of a vaginal progesterone gel in estrogen-treated postmenopausal women. Am J Obstet Gynecol 1997;177:937–41
40. H.N.Hodis, W.J.Mack, D.Shoupe, et al. Methods and baseline cardiovascular data from the Early versus Late Intervention Trial with Estradiol testing the menopausal hormone timing hypothesis. Menopause 2015;22:391–401
41. H.B.Leonetti, K.J.Wilson, J.N.Anasti Topical progesterone cream has an antiproliferative effect on estrogen-stimulated endometrium. Fertil Steril 2003;79:221–2
42. H.B.Leonetti, J.Landes, D.Steinberg, J.N.Anasti Transdermal progesterone cream as an alternative progestin in hormone therapy. Altern Ther Health Med 2005;11:36–8
43. A.Vashisht, F.Wadsworth, A.Carey, B.Carey, J.Studd Bleeding profiles and effects on the endometrium for women using a novel combination of transdermal oestradiol and natural progesterone cream as part of a continuous combined hormone replacement regime. BJOG 2005;112:1402–6
44. B.G.Wren, K.McFarland, L.Edwards Micronised transdermal progesterone and endometrial response. Lancet 1999;354:1447–8
45. B.G.Wren, K.McFarland, L.Edwards, et al. Effect of sequential transdermal progesterone cream on endometrium, bleeding pattern, and plasma progesterone and salivary progesterone levels in postmenopausal women. Climacteric 2000;3:155–60
46. F.M.Jane, S.R.Davis A practitioner's toolkit for managing the menopause. Climacteric 2014;17:564–79
47. G.Sarri, M.Davies, M.A.Lumsden, Guideline Development Group. Diagnosis and management of menopause: summary of NICE guidance. BMJ 2015;351:h5746
48. C.A.Stuenkel, S.R.Davis, A.Gompel, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015;100:3975–4011
49. North American Menopause. The 2012 hormone therapy position statement of The North American Menopause Society. Menopause 2012;19:257–71
50. J.V.Pinkerton, N.Santoro Compounded bioidentical hormone therapy: identifying use trends and knowledge gaps among US women. Menopause 2015;22:926–36
51. J.V.Pinkerton Think twice before prescribing custom-compounded bioidentical hormone therapy. J Womens Health (Larchmt) 2014;23:631–3
52. J.V.Pinkerton What are the concerns about custom-compounded “bioidentical” hormone therapy? Menopause 2014;21:1298–300
53. Committee for Medicinal Products for Human Use European Medicines Agency. Guideline on clinical investigation of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women. EMEA/CHMP/021/97 Rev. 1, October 2005